---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-090787"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T00:53:31.320054+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biodesix raises ~$51.6M in oversubscribed common offering and convertible preferred placement

## Summary
- Net proceeds ~$51.6M from 17.4M shares common at $1.15/share and 760,857 Series A Preferred at $46/share.
- Series A Preferred automatically converts to 40 common shares per preferred share upon stockholder approval, up to 30.4M common shares.
- Management and directors participated in the private placement; 90-day lock-up on common shares.
- Funds to be used for commercial expansion, product pipeline, R&D, and general corporate purposes.

## SEC filing metadata
- accession: 0001193125-24-090787
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000119312524090787/0001193125-24-090787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000119312524090787/d779805d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-090787
- JSON: https://secwatch.observer/filing/0001193125-24-090787.json
- Plain text: https://secwatch.observer/filing/0001193125-24-090787.txt

## Key facts
- Governance Changes
  BIODESIX INC: Filed Certificate of Designations for Series A Non-Voting Convertible Preferred Stock (effective 2024-04-08).
  - Change: charter amendment
  - Effective: 2024-04-08
  source text: On April 8, 2024, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “Certificate of Designations”) in connection with the Concurrent Private Placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000119312524090787/0001193125-24-090787-index.htm
- Material Agreements
  BIODESIX INC entered into Securities Purchase Agreements with various investors, including certain members of management, certain of its directors and funds affiliated with those directors valued at 760,857 shares of Series A Non-Voting Convertible Preferred Stock at $46.00 per share for aggregate (effective 2024-04-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: various investors, including certain members of management, certain of its directors and funds affiliated with those directors
  - Value: 760,857 shares of Series A Non-Voting Convertible Preferred Stock at $46.00 per share for aggregate
  - Effective: 2024-04-05
  source text: On April 5, 2024, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with various investors, including certain members of management, certain of its directors and funds affiliated with those directors (the “Investors”) for the issuance and sale by the Company of an aggregate of 760,857 shares of Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) in an offering (the “Concurrent Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000119312524090787/0001193125-24-090787-index.htm
- Material Agreements
  BIODESIX INC entered into Underwriting Agreement with TD Securities (USA) LLC, William Blair & Company, L.L.C., and Canaccord Genuity LLC valued at 17,391,832 shares of Common Stock at $1.15 per share for approximately $18.4 million net proceeds (effective 2024-04-05).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: TD Securities (USA) LLC, William Blair & Company, L.L.C., and Canaccord Genuity LLC
  - Value: 17,391,832 shares of Common Stock at $1.15 per share for approximately $18.4 million net proceeds
  - Effective: 2024-04-05
  source text: On April 9, 2024, the Company closed an underwritten offering (the “Offering”) of 17,391,832 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The Common Stock was issued and sold pursuant to an underwriting agreement (the “Underwriting Agreement”), dated April 5, 2024, by and between the Company and TD Securities (USA) LLC, William Blair & Company, L.L.C., and Canaccord Genuity LLC as representatives of the underwriters, at a price to the public of $1.15 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000119312524090787/0001193125-24-090787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.